UK, US work on Aids cure

– Britain’s GlaxoSmithKline (GSK), which decided last week to retain rather than float off its HIV drugs business, is to collaborate with US scientists in developing a cure for Aids.

Until recently, many researchers were reluctant to even discuss the possibility of curing the disease caused by HIV, which infects 35 million people worldwide, since the obstacles seemed insurmountable.

But after a 30-year battle to keep HIV at bay with antiretroviral drugs, there is growing optimism a cure is feasible.

The case of Timothy Brown, the so-called “Berlin patient” whose HIV was eradicated by a complex treatment for leukaemia in 2007, marked the first cure and the science has been advancing since then.

GSK is tapping into the latest expertise by creating an HIV Cure centre with the University of North Carolina (UNC) at Chapel Hill and establishing a new jointly-owned company.

The drugmaker said yesterday it would invest $20 million to help fund the work for an initial five years.

Scientists will study various cure options, including a so-called “shock-and-kill” strategy developed at UNC, which unmasks dormant HIV hiding in white blood cells, so that it can be attacked by a boosted immune system. – Reuters

London